ETFs & MarketsFreeFDA Rejection for Summit's Lung Cancer Drug: What it Means for Biotech ETFs
The U.S. Food and Drug Administration (FDA) has declined approval for Summit's lung cancer treatment, a decision that could pressure shares of the pharmaceutical company. This regulatory setback raises questions for investors holding biotech-focused exchange-traded funds (ETFs) and highlights the inherent risks in drug development.